The Challenge, Approval and Future of TCR T Cell Therapy

Presented By: Kristin Anderson, PhD Speaker Biography: Dr. Kristin G. Anderson is an Assistant Professor of Microbiology, Immunology and Cancer Biology at the University of Virginia. Dr. Anderson received her Ph.D. in Immunology from the University of Minnesota, where she studied T cell responses to lung infection and developed a method that is now widely used in the field to discriminate and isolate intravascular from tissue leukocytes. During her postdoctoral training, she applied her immunology training to the field of cancer biology and translational immunotherapy. Her current research focuses on developing molecular engineering strategies to improve T cell killing in ovarian cancer, with the ultimate goal of translating her findings into treatment protocols for patients. She leads a team that uses patient samples to identify immunosuppressive features in the tumor microenvironment, then uses mouse models of cancer that recapitulate these features to evaluate strategies that improve the migration, persistence, and function of genetically engineered anti-tumor T cells. Webinar: The Challenge, Approval and Future of TCR T Cell Therapy Webinar Abstract: Advances in cell and gene therapy have led to U.S. Food and Drug Administration approved adoptive cell therapies to treat hematological malignancies and solid tumors. There is great enthusiasm in the immune-oncology field for engineered cellular therapies, which can unleash the true killing potential of cytotoxic T cells. Indeed, T cell responses can now be engineered with a desired specificity, avidity and function, regardless of the endogenous T cell repertoire. Moreover, T cells expressing a tumor/self-antigen-targeting chimeric antigen receptor or high-affinity T cell receptor (TCR) can be engineered to have enhanced tumor homing, proliferation, persistence, and antitumor function. In this session, we will discuss the recent milestones and future challenges facing the field of engineered T cell therapy with a focus on TCR-engineered T cells. Labroots on Social: Facebook:   / labrootsinc   Twitter:   / labroots   LinkedIn:   / labroots   Instagram:   / labrootsinc   Pinterest:   / labroots   SnapChat: labroots_inc